These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 21965073)

  • 1. Overview of the use of transgenic animals in CNS drug discovery.
    Nestler EJ; Olivier B
    Curr Protoc Pharmacol; 2001 May; Chapter 5():Unit5.20. PubMed ID: 21965073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CNS Target Identification and Validation: Avoiding the Valley of Death or Naive Optimism?
    Hutson PH; Clark JA; Cross AJ
    Annu Rev Pharmacol Toxicol; 2017 Jan; 57():171-187. PubMed ID: 27575715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges in the search for drugs to treat central nervous system disorders.
    Enna SJ; Williams M
    J Pharmacol Exp Ther; 2009 May; 329(2):404-11. PubMed ID: 19182069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zebrafish models in neuropsychopharmacology and CNS drug discovery.
    Khan KM; Collier AD; Meshalkina DA; Kysil EV; Khatsko SL; Kolesnikova T; Morzherin YY; Warnick JE; Kalueff AV; Echevarria DJ
    Br J Pharmacol; 2017 Jul; 174(13):1925-1944. PubMed ID: 28217866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders.
    Conn PJ; Lindsley CW; Meiler J; Niswender CM
    Nat Rev Drug Discov; 2014 Sep; 13(9):692-708. PubMed ID: 25176435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CNS drug development - lost in translation?
    Talevi A; Bellera CL; Di Ianni M; Gantner M; Bruno-Blanch LE; Castro EA
    Mini Rev Med Chem; 2012 Sep; 12(10):959-70. PubMed ID: 22420574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Applications of imaging biomarkers in the early clinical development of central nervous system therapeutic agents.
    Cole PE; Schwarz AJ; Schmidt ME
    Clin Pharmacol Ther; 2012 Feb; 91(2):315-20. PubMed ID: 22218072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospects for the development of epigenetic drugs for CNS conditions.
    Szyf M
    Nat Rev Drug Discov; 2015 Jul; 14(7):461-74. PubMed ID: 26000723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative psychology and the grand challenge of drug discovery in psychiatry and neurodegeneration.
    Brunner D; Balcı F; Ludvig EA
    Behav Processes; 2012 Feb; 89(2):187-95. PubMed ID: 22155361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Securing the future of drug discovery for central nervous system disorders.
    Andersen PH; Moscicki R; Sahakian B; Quirion R; Krishnan R; Race T; Phillips A;
    Nat Rev Drug Discov; 2014 Dec; 13(12):871-2. PubMed ID: 25435203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetically modified mice in neuropharmacology.
    Brusa R
    Pharmacol Res; 1999 Jun; 39(6):405-19. PubMed ID: 10373238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting neuronal function for CNS drug discovery.
    Hempel CM; Werley CA; Dempsey GT; Gerber DJ
    Drug Discov Today Technol; 2017 Mar; 23():17-25. PubMed ID: 28647082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Start small and stay small. Minimizing attrition in the clinic with a focus on CNS therapeutics.
    Nienaber V
    Curr Top Med Chem; 2009; 9(18):1688-704. PubMed ID: 19929834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Animal models of CNS disorders.
    McGonigle P
    Biochem Pharmacol; 2014 Jan; 87(1):140-9. PubMed ID: 23811310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional Chemical Groups that May Likely Become a Source for the Synthesis of Novel Central Nervous System (CNS) Acting Drugs.
    Saganuwan SA
    Cent Nerv Syst Agents Med Chem; 2017; 17(3):178-186. PubMed ID: 28464765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proceedings of the 2013 CINP summit: innovative partnerships to accelerate CNS drug discovery for improved patient care.
    Phillips AG; Hongaard-Andersen P; Moscicki RA; Sahakian B; Quirion R; Krishnan KR; Race T
    Int J Neuropsychopharmacol; 2014 Dec; 18(3):. PubMed ID: 25542690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of PET ligand discovery to CNS drug development.
    Schmidt ME; Andrés JI
    Future Med Chem; 2017 Mar; 9(4):351-356. PubMed ID: 28263084
    [No Abstract]   [Full Text] [Related]  

  • 18. Role of Academic Drug Discovery in the Quest for New CNS Therapeutics.
    Yokley BH; Hartman M; Slusher BS
    ACS Chem Neurosci; 2017 Mar; 8(3):429-431. PubMed ID: 28195461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An audience with...Luca Santarelli. Interview by Alexandra Flemming.
    Santarelli L
    Nat Rev Drug Discov; 2013 Jan; 12(1):14-5. PubMed ID: 23274461
    [No Abstract]   [Full Text] [Related]  

  • 20. The genetic and epigenetic landscape for CNS drug discovery targeting cross-diagnostic behavioral domains.
    de Mooij-van Malsen AJ; Pjetri E; Kas MJ
    Eur J Pharmacol; 2015 Apr; 753():135-9. PubMed ID: 25107283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.